Clinical trials
Observational Hemangioma, Capillary trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 3 |
| Not yet recruiting | 2 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| West China Hospital | 3 |
| University Hospital, Montpellier | 2 |
| Central Hospital, Nancy, France | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Columbia University | 1 |
| Daniel Benjamin | 1 |
| Medical College of Wisconsin | 1 |
| University Hospital Dubrava | 1 |
| University of California, San Francisco | 1 |
| University of Chicago | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemangioma, Capillary | 15 |
| Hemangioma | 4 |
| Hemangioma, Cavernous | 2 |
| Adenoviridae Infections | 1 |
| Anxiety Disorders | 1 |
| Arrhythmias, Cardiac | 1 |
| Astrocytoma | 1 |
| Autistic Disorder | 1 |
| Bipolar Disorder | 1 |
| Bradycardia | 1 |
Trials
Showing 26 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.